Trial Profile

A Phase II Randomized Placebo-controlled Study to Assess the Impact on Outcome of Eltrombopag Administered to Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 31 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eltrombopag (Primary) ; Cytarabine; Daunorubicin; Lomustine
Indications Acute myeloid leukaemia
Focus Therapeutic Use
Acronyms EPAG2015

Most Recent Events

29 Oct 2024 Planned End Date changed from 1 Sep 2024 to 30 Jul 2026.
13 Dec 2022 Results assessing impact on outcome of eltrombopag administered to elderly AML pts receiving induction chemotherapy presented at the 64th American Society of Hematology Annual Meeting and Exposition
28 Jun 2021 Planned primary completion date changed from 1 Sep 2020 to 1 Jul 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com